TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31391297

Group type: EXPERIMENTAL
Intervention: Resistance and high-intensity interval training (RT-HIIT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and high-intensity interval training (AT-HIIT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240
Study: 30121291

Group type: EXPERIMENTAL
Intervention: fezakinumab
Number of subjects: 59

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study: 28267243

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (non-Japanese patients)
Number of subjects: 44
Study: 25636519

Group type: EXPERIMENTAL
Intervention: Instructor-driven assistant push
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard CC (single-rescuer group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subject-driven assistant push
Number of subjects: 41
Study: 23521386

Group type: EXPERIMENTAL
Intervention: Assertive outreach community management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 22156354

Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 20 mg and domperidone 3 x 10 mg for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole 2 x 20 mg (control group)
Number of subjects: 60
Study: 19662959

Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 0
Study: 16678543

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14717754

Group type: EXPERIMENTAL
Intervention: Intervention group (mammography centers with tools and systems for patient notification)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (mammography centers without intervention)
Number of subjects: 11
Study: 12212638

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.04 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9794507

Group type: EXPERIMENTAL
Intervention: AUCs truncated at four times Tmax
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: AUCs truncated at 3*Tmax
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: AUCs truncated at 72 hours (AUC(0-72))
Number of subjects: 2214

Group type: COMPARATOR
Intervention: AUCs extrapolated to infinity (AUC(inf))
Number of subjects: 2214
Study: 8775995

Group type: EXPERIMENTAL
Intervention: Combination of anti‐gliadin IgG and anti‐endomysium IgA
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination of anti‐gliadin IgG and anti‐endomysium IgA plus anti‐gliadin IgA
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Serological screening
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Early dietary treatment
Number of subjects: 88
Study: 2692883

Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms/nasal cavity morning and evening
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 922756

Group type: EXPERIMENTAL
Intervention: CCNU (100 mg/m2 orally every 6 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: methyl-CCNU (150 mg/m2 orally every 6 weeks)
Number of subjects: 57
Study: 31335757

Group type: EXPERIMENTAL
Intervention: Discharge preparation by individual nurses
Number of subjects: 29986
Study: 27179543

Group type: EXPERIMENTAL
Intervention: Continuous chest compression CPR (CCC‐CPR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard CPR (30:2 compression to breath ratio)
Number of subjects: 15
Study: 25693990

Group type: EXPERIMENTAL
Intervention: Feedback with grades
Number of subjects: 83

Group type: COMPARATOR
Intervention: Feedback without grades
Number of subjects: 83
Study: 24735100

Group type: EXPERIMENTAL
Intervention: Insuman (400 IU/mL)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Insuplant
Number of subjects: 169
Study: 22398784

Group type: EXPERIMENTAL
Intervention: apixaban 5 mg orally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enoxaparin 40 mg subcutaneously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: apixaban 5 mg and enoxaparin 40 mg concomitantly
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: apixaban 5 mg followed 6 hours after by enoxaparin 40 mg
Number of subjects: 20
Study: 19279320

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b
Number of subjects: 75

Group type: COMPARATOR
Intervention: GA
Number of subjects: 75
Study: 17157264

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive restructuring and exposure
Number of subjects: 0
Study: 15217657

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (Group Ropi-7.5)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine (Group Ropi-10)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.5% ropivacaine (Group Ropi-5)
Number of subjects: 68
Study: 11576802

Group type: EXPERIMENTAL
Intervention: Distraction Education intervention for parents prior to IV insertion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 44
Study: 9850403

Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax (20 mg/kg, then 15 mg/kg every 8 h for 2 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous Quinimax (8 mg/kg infused over 4 h every 8 h for 2 days)
Number of subjects: 76
Study: 8003055

Group type: EXPERIMENTAL
Intervention: 2.6 gm of omega 3
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1.3 gm of omega 3 + 3 gm of olive oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: 6 gm of olive oil
Number of subjects: 90
Study: 29861076

Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus human albumin (HA) (40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus human albumin (HA)
Number of subjects: 440
Study: 27542601

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) survey prior to surgery
Number of subjects: 132

Group type: COMPARATOR
Intervention: Modified survey without DCE activity
Number of subjects: 132
Study: 23942818

Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: High ligation of saphenous vein (HLS)
Number of subjects: 65
Study: 23106506

Group type: EXPERIMENTAL
Intervention: Porcine bone grafting
Number of subjects: 40

Group type: COMPARATOR
Intervention: No grafting material (Control)
Number of subjects: 40
Study: 20418309

Group type: EXPERIMENTAL
Intervention: Central placement of local anesthetic (posterior cord)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Peripheral placement of local anesthetic (medial or lateral cord)
Number of subjects: 218
Study: 17986497

Group type: EXPERIMENTAL
Intervention: Water-based exercise group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Land-based exercise group
Number of subjects: 64
Study: 16598777

Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 mg bid
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Everolimus 1.0 mg bid
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg bid
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 14598248

Group type: EXPERIMENTAL
Intervention: hospital‐based computer‐assisted sphincter pressure biofeedback
Number of subjects: 171

Group type: COMPARATOR
Intervention: standard care (advice)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: hospital biofeedback plus the use of a home electromyelogram biofeedback device
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: advice plus instruction on sphincter exercises
Number of subjects: 171
Study: 11095338

Group type: EXPERIMENTAL
Intervention: Manning criteria
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Rome I criteria
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Rome II criteria
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: IBS regardless of criteria
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Pain and bowel habit severity
Number of subjects: 4500
Study: 8971430

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg administered orally after a standard breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bumetanide 2 mg administered orally after a standard breakfast
Number of subjects: 17
Study: 1346172

Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5 mg twice a week for 3 months)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 145
Study: 6231104

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 48
Study: 29594933

Group type: EXPERIMENTAL
Intervention: Self-sampling option (individualized CHW-led education with choice of HPV self-sampling or CHW-facilitated navigation to Pap smear)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Outreach (outreach by CHWs and provision of culturally tailored cervical cancer screening information)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Navigation (individualized CHW-led education and navigation to local health care facilities for Pap smear)
Number of subjects: 601
Study: 27743701

Group type: EXPERIMENTAL
Intervention: SCOPA‐COG at baseline and year 5
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: SDMT annually
Number of subjects: 1741
Study: 24373681

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control (no physical therapy)
Number of subjects: 244
Study: 24382182

Group type: EXPERIMENTAL
Intervention: Universal occlusal appliance device (PG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without any treatment (CG)
Number of subjects: 50
Study: 20860092

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CT-CA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 44
Study: 19695404

Group type: EXPERIMENTAL
Intervention: Test formulation of glucosamine sulfate 500 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation of glucosamine sulfate 500 mg
Number of subjects: 22
Study: 15842277

Group type: COMPARATOR
Intervention: Cannula aspiration (CA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Biopsy forceps (BF)
Number of subjects: 200
Study: 12611766

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No LBPP (control)
Number of subjects: 6
Study: 10596845

Group type: EXPERIMENTAL
Intervention: propofol/alfentanil
Number of subjects: 36

Group type: COMPARATOR
Intervention: midazolam/fentanyl
Number of subjects: 36
Study: 8732695

Group type: EXPERIMENTAL
Intervention: Perilymphatic injections of recombinant interleukin-2 (rIL-2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 60
Study: 1878176

Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 24
Study: 6139669

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control medical management
Number of subjects: 75
Study: 27956477

Group type: EXPERIMENTAL
Intervention: Viewing comfort foods (food image)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drawing comfort foods (food art)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Viewing fruits (food image)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drawing fruits (food art)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Viewing comfort foods (food image) for those with clinical symptoms of depression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drawing comfort foods (food art) for those with clinical symptoms of depression
Number of subjects: 60
Study: 27502850

Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Number of subjects: 1500

Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1500
Study: 24807871

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22808716

Group type: EXPERIMENTAL
Intervention: Induction of emotions by manipulating height
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Functional and dysfunctional emotions measured during routines
Number of subjects: 14
Study: 20697803

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day for 14 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 25
Study: 18318083

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 17038256

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) given after tissue oxygenation indicated by PiCO(2) normalization
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enteral nutrition (EN) given at the early stage of recovery from shock (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups received enteral nutrition
Number of subjects: 96
Study: 14633547

Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT morphine 200 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT morphine 50 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IT morphine 0 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg vs 200 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT morphine 100 microg vs 50 microg vs 200 microg
Number of subjects: 60
Study: 10677051

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formulas
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whey and milk protein challenges
Number of subjects: 22
Study: 9058336

Group type: EXPERIMENTAL
Intervention: Collagen barrier material
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene barrier material
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polylactic acid barrier material
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control site (natural colonization of the tooth surface)
Number of subjects: 10
Study: 8393359

Group type: EXPERIMENTAL
Intervention: oral alkali therapy with sodium bicarbonate 2 mmol/kg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: no therapy (control group)
Number of subjects: 170
Study: 3105242

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29301639

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study: 25645978

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 16
Study: 24685998

Group type: EXPERIMENTAL
Intervention: Treatment group (church-based health program)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 221
Study: 22719932

Group type: EXPERIMENTAL
Intervention: Rapid antivenom infusion (20 minute infusion)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Slow antivenom infusion (2 hour infusion)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rapid antivenom infusion
Number of subjects: 104

Group type: COMPARATOR
Intervention: Slow antivenom infusion
Number of subjects: 104
Study: 19833214

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Escitalopram and Citalopram
Number of subjects: 18
Study: 18032762

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 351
Study: 16134010

Group type: EXPERIMENTAL
Intervention: Moderately intoxicating alcohol dose
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 44
Study: 11939442

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg/kg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 63
Study: 10516877

Group type: EXPERIMENTAL
Intervention: Memantine (1‐amino 3,5‐dimethyl‐adamantane hydrochloride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7627863

Group type: EXPERIMENTAL
Intervention: Normal coronary angiography
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pathological coronary angiography
Number of subjects: 45
Study: 2032518

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 309
Study: 7137662

Group type: EXPERIMENTAL
Intervention: Midazolam (10 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diazepam (15 mg)
Number of subjects: 27
Study: 30217513

Group type: EXPERIMENTAL
Intervention: Celiac Ganglia Neurolysis (CGN)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Celiac Plexus Neurolysis (CPN)
Number of subjects: 110
Study: 28218551

Group type: EXPERIMENTAL
Intervention: Surgical protocol A
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Surgical protocol B
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Surgical protocol C
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Surgical protocol D
Number of subjects: 448
Study: 24446238

Group type: EXPERIMENTAL
Intervention: Assist control mode with 6 mL/kg tidal volume and constant flow 60 L/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Assist control mode with 8 mL/kg tidal volume and decelerating flow 40 L/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Various ventilator settings (assist control and pressure support)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiologic variables recorded during varying ventilator settings
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comfort level measured using a 10-point Borg scale
Number of subjects: 20
Study: 24956001

Group type: EXPERIMENTAL
Intervention: Positive messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positively-framed messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negatively-framed messages
Number of subjects: 0
Study: 22866000

Group type: EXPERIMENTAL
Intervention: Ricotta cheese (210 g/day) plus habitual diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Habitual diet with no additional intervention
Number of subjects: 40
Study: 20431329

Group type: EXPERIMENTAL
Intervention: Active gamma ventral capsulotomy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Sham radiosurgical procedure
Number of subjects: 1
Study: 17353168

Group type: EXPERIMENTAL
Intervention: Telemedicine system for the transmission of morpho/immunological data
Number of subjects: 0
Study: 15867104

Group type: EXPERIMENTAL
Intervention: Nefazodone (100 to 600 mg/d)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CBASP (twice weekly for weeks 1-4, weekly thereafter)
Number of subjects: 140
Study: 12419087

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) 0.625 mg daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol 50 microg
Number of subjects: 21
Study: 10102258

Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 4 months, 5 days/week, 40 minutes/session
Number of subjects: 79

Group type: COMPARATOR
Intervention: No Physical Training (no PT)
Number of subjects: 79
Study: 7768364

Group type: EXPERIMENTAL
Intervention: Metronidazole (20 mg/kg body wt) daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2138436

Group type: EXPERIMENTAL
Intervention: loratadine 40 mg once daily
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: clemastine 1 mg twice daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 6643055

Group type: EXPERIMENTAL
Intervention: Anthralin therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined therapy with anthralin and steroid
Number of subjects: 10
Study: 31778949

Group type: EXPERIMENTAL
Intervention: Self-reported NFOD history
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Medically-verified NFOD history
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Both self-reported and medically-verified NFOD history
Number of subjects: 1307

Group type: COMPARATOR
Intervention: No NFOD history
Number of subjects: 1307
Study: 31655788

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically diverse intervention including peer counselor and professional support
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 39
Study: 27997064

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 26402009

Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired Older Adults (ST‐CI)
Number of subjects: 39
Study: 24395676

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study: 22313135

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) plus recombinant LH (rLH)
Number of subjects: 0
Study: 19444703

Group type: EXPERIMENTAL
Intervention: Low-fat diet (6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-fat diet (6 weeks)
Number of subjects: 18